Equity at the Intersection of Heart Failure and Interventions: A Review of the Spectrum From Ambulatory Care to Cardiogenic Shock.

Nonetheless, in the intention-to-treat population, Impella showed a trend toward lower rates of MAE in the per-protocol population (34% vs 42%; P = .09) and lower rates of 90-day MAE (40% vs 51%; P = .023). 64 A recent prespecified, retrospective analysis by race of the PROTECT II trial showed similar rates of MAE at 90 days between White and non-White patients (40.9% and 44.5%; P = .53). 66 The ongoing Impella-Supported PCI in High-Risk Patients with Complex CAD and Reduced Left Ventricular Function trial (PROTECT IV), 67 may provide further information regarding the use of MCSD in racial/ethnic minorities with reduced EF undergoing high risk PCI.

also in 53,322 other papers